Amarin Reports Potential Legacy Effect of Icosapent Ethyl in New REDUCE-IT Analysis
Dublin, Ireland & Bridgewater, N.J. – August 28, 2026 Amarin Corporation announced new post hoc findings from the landmark...
ADC AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery FDA fda approval FDA clearance Gene Therapy healthcare technology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
Dublin, Ireland & Bridgewater, N.J. – August 28, 2026 Amarin Corporation announced new post hoc findings from the landmark...
NAARDEN, The Netherlands; MIAMI, USA; and FLORENCE, Italy, July 24, 2026 NewAmsterdam Pharma and its commercialization partner Menarini Group...
LA JOLLA, Calif., May 26, 2026 MediciNova announced the completion of the Last Patient Last Visit (LPLV) in its...
